EGFR and lung cancer: As proven by several large-scale clinical trials, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) are highly effective in lung cancer patients harboring EGFR activating mutations, mainly, deletions in exon 19 (Del19) and a L858R mutation in exon 219–13.